Immunocore Holdings Ltd Total Assets
Immunocore Holdings Ltd total assets. Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) holds total assets worth $1.12 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Immunocore Holdings Ltd market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Immunocore Holdings Ltd (2013–2025)
Total assets of Immunocore Holdings Ltd from 2013 to 2025. This chart illustrates how Immunocore Holdings Ltd's total assets have evolved over time, based on quarterly financial data. See Immunocore Holdings Ltd share price for real-time trading data and today's change.
Immunocore Holdings Ltd - Asset Composition Analysis
Immunocore Holdings Ltd Total Assets Breakdown (December 2025)
Immunocore Holdings Ltd total assets breakdown as of December 2025. Immunocore Holdings Ltd's total assets of $1.12 Billion consist of 93.4% current assets and 6.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.8% |
| Accounts Receivable | $73.98 Million | 6.9% |
| Inventory | $6.74 Million | 0.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Immunocore Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IMCR working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunocore Holdings Ltd's current assets represent 93.4% of total assets in 2025, an increase from 92.1% in 2013.
- Cash Position: Cash and equivalents constituted 43.8% of total assets in 2025, down from 83.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 6.9% of total assets.
Immunocore Holdings Ltd Competitors by Total Assets
Key competitors of Immunocore Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Immunocore Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.47 | 5.89 | 5.24 |
| Quick Ratio | 4.44 | 5.86 | 5.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $815.85 Million | $832.22 Million | $234.55 Million |
Immunocore Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Immunocore Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.87 |
| Latest Market Cap to Assets Ratio | 1.40 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | $1.07 Billion |
| Market Capitalization | $1.50 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Immunocore Holdings Ltd's assets above their book value (1.40x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Immunocore Holdings Ltd's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Immunocore Holdings Ltd (2013–2025)
The table below shows the annual total assets of Immunocore Holdings Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.07 Billion | +5.72% |
| 2024-12-31 | $1.01 Billion | +69.10% |
| 2023-12-31 | $597.00 Million | +13.33% |
| 2022-12-31 | $526.76 Million | +29.34% |
| 2021-12-31 | $407.28 Million | +106.54% |
| 2020-12-31 | $197.19 Million | -19.82% |
| 2019-12-31 | $245.94 Million | +25.62% |
| 2018-12-31 | $195.78 Million | -1.14% |
| 2017-12-31 | $198.04 Million | -9.60% |
| 2016-12-31 | $219.08 Million | -19.91% |
| 2015-12-31 | $273.53 Million | +349.36% |
| 2014-12-31 | $60.87 Million | +210.86% |
| 2013-12-31 | $19.58 Million | -- |
About Immunocore Holdings Ltd
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more